Cargando…

Salvage therapy with brentuximab-vedotin and bendamustine for patients with R/R PTCL: a retrospective study from the LYSA group

Patients with relapsed or refractory (R/R) peripheral T-cell lymphomas (PTCL) have a poor prognosis. Bendamustine (B) and brentuximab-vedotin (Bv) have shown interesting results in this setting. However, little information is available about their efficacy in combination. This multicenter and retros...

Descripción completa

Detalles Bibliográficos
Autores principales: Aubrais, Raphaelle, Bouabdallah, Krimo, Chartier, Loic, Herbaux, Charles, Banos, Anne, Brice, Pauline, Sibon, David, Schiano, Jean Marc, Cluzeau, Thomas, Laribi, Kamel, Le Calloch, Ronan, Bellal, Mathieu, Delapierre, Baptiste, Daguindau, Nicolas, Amorim, Sandy, Agbetiafa, Kossi, Chauchet, Adrien, Besson, Caroline, Durot, Eric, Bonnet, Christophe, Fouillet, Ludovic, Bijou, Fontanet, Tournilhac, Olivier, Gaulard, Philippe, Parrens, Marie-Cécile, Damaj, Gandhi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10539874/
https://www.ncbi.nlm.nih.gov/pubmed/36477770
http://dx.doi.org/10.1182/bloodadvances.2022008524
_version_ 1785113597553147904
author Aubrais, Raphaelle
Bouabdallah, Krimo
Chartier, Loic
Herbaux, Charles
Banos, Anne
Brice, Pauline
Sibon, David
Schiano, Jean Marc
Cluzeau, Thomas
Laribi, Kamel
Le Calloch, Ronan
Bellal, Mathieu
Delapierre, Baptiste
Daguindau, Nicolas
Amorim, Sandy
Agbetiafa, Kossi
Chauchet, Adrien
Besson, Caroline
Durot, Eric
Bonnet, Christophe
Fouillet, Ludovic
Bijou, Fontanet
Tournilhac, Olivier
Gaulard, Philippe
Parrens, Marie-Cécile
Damaj, Gandhi
author_facet Aubrais, Raphaelle
Bouabdallah, Krimo
Chartier, Loic
Herbaux, Charles
Banos, Anne
Brice, Pauline
Sibon, David
Schiano, Jean Marc
Cluzeau, Thomas
Laribi, Kamel
Le Calloch, Ronan
Bellal, Mathieu
Delapierre, Baptiste
Daguindau, Nicolas
Amorim, Sandy
Agbetiafa, Kossi
Chauchet, Adrien
Besson, Caroline
Durot, Eric
Bonnet, Christophe
Fouillet, Ludovic
Bijou, Fontanet
Tournilhac, Olivier
Gaulard, Philippe
Parrens, Marie-Cécile
Damaj, Gandhi
author_sort Aubrais, Raphaelle
collection PubMed
description Patients with relapsed or refractory (R/R) peripheral T-cell lymphomas (PTCL) have a poor prognosis. Bendamustine (B) and brentuximab-vedotin (Bv) have shown interesting results in this setting. However, little information is available about their efficacy in combination. This multicenter and retrospective study aimed to evaluate the efficacy and safety of the combination of BBv in patients with noncutaneous R/R PTCL among 21 LYSA centers in France and Belgium. The primary objective was the overall response rate. A total of 82 patients with R/R PTCL were included. The best overall response rate (ORR) was 68%, with 49% of patients in complete response (CR). In multivariable analysis, only the disease status after the last regimen (relapse vs refractory) was associated with the response with an ORR of 83% vs 57%. Median duration of response was 15.4 months for patients in CR. With a median follow-up of 22 months, the median progression free survival (PFS) and overall survival (OS) were 8.3 and 26.3 months respectively. Moreover, patients in CR, who underwent an allogeneic transplant, had a better outcome than patients who did not with a median PFS and OS of 19.3 vs 4.8 months and not reached vs 12.4 months, respectively. Fifty-nine percent of patients experienced grade 3/4 adverse events that were mainly hematologic. BBv is highly active in patients with R/R PTCL and should be considered as a one of the best options of immunochemotherapy salvage combination in this setting and particularly as a bridge to allogeneic transplant for eligible patients.
format Online
Article
Text
id pubmed-10539874
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher The American Society of Hematology
record_format MEDLINE/PubMed
spelling pubmed-105398742023-09-30 Salvage therapy with brentuximab-vedotin and bendamustine for patients with R/R PTCL: a retrospective study from the LYSA group Aubrais, Raphaelle Bouabdallah, Krimo Chartier, Loic Herbaux, Charles Banos, Anne Brice, Pauline Sibon, David Schiano, Jean Marc Cluzeau, Thomas Laribi, Kamel Le Calloch, Ronan Bellal, Mathieu Delapierre, Baptiste Daguindau, Nicolas Amorim, Sandy Agbetiafa, Kossi Chauchet, Adrien Besson, Caroline Durot, Eric Bonnet, Christophe Fouillet, Ludovic Bijou, Fontanet Tournilhac, Olivier Gaulard, Philippe Parrens, Marie-Cécile Damaj, Gandhi Blood Adv Lymphoid Neoplasia Patients with relapsed or refractory (R/R) peripheral T-cell lymphomas (PTCL) have a poor prognosis. Bendamustine (B) and brentuximab-vedotin (Bv) have shown interesting results in this setting. However, little information is available about their efficacy in combination. This multicenter and retrospective study aimed to evaluate the efficacy and safety of the combination of BBv in patients with noncutaneous R/R PTCL among 21 LYSA centers in France and Belgium. The primary objective was the overall response rate. A total of 82 patients with R/R PTCL were included. The best overall response rate (ORR) was 68%, with 49% of patients in complete response (CR). In multivariable analysis, only the disease status after the last regimen (relapse vs refractory) was associated with the response with an ORR of 83% vs 57%. Median duration of response was 15.4 months for patients in CR. With a median follow-up of 22 months, the median progression free survival (PFS) and overall survival (OS) were 8.3 and 26.3 months respectively. Moreover, patients in CR, who underwent an allogeneic transplant, had a better outcome than patients who did not with a median PFS and OS of 19.3 vs 4.8 months and not reached vs 12.4 months, respectively. Fifty-nine percent of patients experienced grade 3/4 adverse events that were mainly hematologic. BBv is highly active in patients with R/R PTCL and should be considered as a one of the best options of immunochemotherapy salvage combination in this setting and particularly as a bridge to allogeneic transplant for eligible patients. The American Society of Hematology 2022-12-10 /pmc/articles/PMC10539874/ /pubmed/36477770 http://dx.doi.org/10.1182/bloodadvances.2022008524 Text en © 2023 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Lymphoid Neoplasia
Aubrais, Raphaelle
Bouabdallah, Krimo
Chartier, Loic
Herbaux, Charles
Banos, Anne
Brice, Pauline
Sibon, David
Schiano, Jean Marc
Cluzeau, Thomas
Laribi, Kamel
Le Calloch, Ronan
Bellal, Mathieu
Delapierre, Baptiste
Daguindau, Nicolas
Amorim, Sandy
Agbetiafa, Kossi
Chauchet, Adrien
Besson, Caroline
Durot, Eric
Bonnet, Christophe
Fouillet, Ludovic
Bijou, Fontanet
Tournilhac, Olivier
Gaulard, Philippe
Parrens, Marie-Cécile
Damaj, Gandhi
Salvage therapy with brentuximab-vedotin and bendamustine for patients with R/R PTCL: a retrospective study from the LYSA group
title Salvage therapy with brentuximab-vedotin and bendamustine for patients with R/R PTCL: a retrospective study from the LYSA group
title_full Salvage therapy with brentuximab-vedotin and bendamustine for patients with R/R PTCL: a retrospective study from the LYSA group
title_fullStr Salvage therapy with brentuximab-vedotin and bendamustine for patients with R/R PTCL: a retrospective study from the LYSA group
title_full_unstemmed Salvage therapy with brentuximab-vedotin and bendamustine for patients with R/R PTCL: a retrospective study from the LYSA group
title_short Salvage therapy with brentuximab-vedotin and bendamustine for patients with R/R PTCL: a retrospective study from the LYSA group
title_sort salvage therapy with brentuximab-vedotin and bendamustine for patients with r/r ptcl: a retrospective study from the lysa group
topic Lymphoid Neoplasia
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10539874/
https://www.ncbi.nlm.nih.gov/pubmed/36477770
http://dx.doi.org/10.1182/bloodadvances.2022008524
work_keys_str_mv AT aubraisraphaelle salvagetherapywithbrentuximabvedotinandbendamustineforpatientswithrrptclaretrospectivestudyfromthelysagroup
AT bouabdallahkrimo salvagetherapywithbrentuximabvedotinandbendamustineforpatientswithrrptclaretrospectivestudyfromthelysagroup
AT chartierloic salvagetherapywithbrentuximabvedotinandbendamustineforpatientswithrrptclaretrospectivestudyfromthelysagroup
AT herbauxcharles salvagetherapywithbrentuximabvedotinandbendamustineforpatientswithrrptclaretrospectivestudyfromthelysagroup
AT banosanne salvagetherapywithbrentuximabvedotinandbendamustineforpatientswithrrptclaretrospectivestudyfromthelysagroup
AT bricepauline salvagetherapywithbrentuximabvedotinandbendamustineforpatientswithrrptclaretrospectivestudyfromthelysagroup
AT sibondavid salvagetherapywithbrentuximabvedotinandbendamustineforpatientswithrrptclaretrospectivestudyfromthelysagroup
AT schianojeanmarc salvagetherapywithbrentuximabvedotinandbendamustineforpatientswithrrptclaretrospectivestudyfromthelysagroup
AT cluzeauthomas salvagetherapywithbrentuximabvedotinandbendamustineforpatientswithrrptclaretrospectivestudyfromthelysagroup
AT laribikamel salvagetherapywithbrentuximabvedotinandbendamustineforpatientswithrrptclaretrospectivestudyfromthelysagroup
AT lecallochronan salvagetherapywithbrentuximabvedotinandbendamustineforpatientswithrrptclaretrospectivestudyfromthelysagroup
AT bellalmathieu salvagetherapywithbrentuximabvedotinandbendamustineforpatientswithrrptclaretrospectivestudyfromthelysagroup
AT delapierrebaptiste salvagetherapywithbrentuximabvedotinandbendamustineforpatientswithrrptclaretrospectivestudyfromthelysagroup
AT daguindaunicolas salvagetherapywithbrentuximabvedotinandbendamustineforpatientswithrrptclaretrospectivestudyfromthelysagroup
AT amorimsandy salvagetherapywithbrentuximabvedotinandbendamustineforpatientswithrrptclaretrospectivestudyfromthelysagroup
AT agbetiafakossi salvagetherapywithbrentuximabvedotinandbendamustineforpatientswithrrptclaretrospectivestudyfromthelysagroup
AT chauchetadrien salvagetherapywithbrentuximabvedotinandbendamustineforpatientswithrrptclaretrospectivestudyfromthelysagroup
AT bessoncaroline salvagetherapywithbrentuximabvedotinandbendamustineforpatientswithrrptclaretrospectivestudyfromthelysagroup
AT duroteric salvagetherapywithbrentuximabvedotinandbendamustineforpatientswithrrptclaretrospectivestudyfromthelysagroup
AT bonnetchristophe salvagetherapywithbrentuximabvedotinandbendamustineforpatientswithrrptclaretrospectivestudyfromthelysagroup
AT fouilletludovic salvagetherapywithbrentuximabvedotinandbendamustineforpatientswithrrptclaretrospectivestudyfromthelysagroup
AT bijoufontanet salvagetherapywithbrentuximabvedotinandbendamustineforpatientswithrrptclaretrospectivestudyfromthelysagroup
AT tournilhacolivier salvagetherapywithbrentuximabvedotinandbendamustineforpatientswithrrptclaretrospectivestudyfromthelysagroup
AT gaulardphilippe salvagetherapywithbrentuximabvedotinandbendamustineforpatientswithrrptclaretrospectivestudyfromthelysagroup
AT parrensmariececile salvagetherapywithbrentuximabvedotinandbendamustineforpatientswithrrptclaretrospectivestudyfromthelysagroup
AT damajgandhi salvagetherapywithbrentuximabvedotinandbendamustineforpatientswithrrptclaretrospectivestudyfromthelysagroup
AT salvagetherapywithbrentuximabvedotinandbendamustineforpatientswithrrptclaretrospectivestudyfromthelysagroup